Table 3.

Overview of clinical studies which administered a booster dose of Ad26.ZEBOV.

Study phase	Study number	Location	Population	Method	Booster dose administration
Phase 2	EBL2002	Burkina Faso, Côte D’Ivoire, Kenya Uganda	• Healthy adults • HIV-infected adults • 4–11 years • 12–17 years	Randomized, placebo-controlled, observer-blind	• 1 year
	EBL2011	Sierra Leone	• 1–3 years • 4–11 years	Open label	• 3.1 years • 3.8 years
Phase 3	EBL3001	Sierra Leone	• Healthy adults	Staged study with an open-label, uncontrolled Stage 1 followed by a randomized, controlled, double-blind Stage 2	• 2 years

HIV, human immunodeficiency virus.